Exenatide (Byetta/Bydureon) for Type 2 Diabetes — Weight & Metabolism
First-in-class GLP-1 receptor agonist available as twice-daily and once-weekly formulations for type 2 diabetes management.
Overview
Exenatide is a synthetic exendin-4 analog and the first GLP-1 receptor agonist approved by the FDA (2005), derived from Gila monster (Heloderma suspectum) saliva. Available as Byetta (twice-daily immediate-release) and Bydureon/Bydureon BCise (once-weekly extended-release microsphere formulation). The EXSCEL cardiovascular outcomes trial (n=14,752, median 3.2 years) confirmed cardiovascular safety with a trend toward benefit (HR 0.91, 95% CI 0.83-1.00, p=0.06 for superiority). HbA1c reductions of 0.8-1.5% across clinical trials with 2-4 kg weight loss. Exenatide has historical significance as the compound that validated the GLP-1 therapeutic class. PMID: 28881470, 22047804, 15509184.
Indications
- Type 2 diabetes mellitus as adjunct to diet and exercise
- Add-on therapy to metformin, sulfonylurea, thiazolidinedione, or basal insulin
- Patients preferring twice-daily (Byetta) or once-weekly (Bydureon) GLP-1 RA options
Mechanism of Action
Reduced GLP-1 secretion and action contribute to impaired insulin response and postprandial hyperglycemia
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Exenatide | 5 mcg | Twice daily (within 60 min before meals) | Starting dose for first month; administer before two main meals >=6 hours apart |
| Exenatide | 10 mcg | Twice daily (within 60 min before meals) | Maintenance dose after 1 month; provides additional HbA1c reduction |
| Exenatide ER | 2 mg | Once weekly | Fixed dose; microsphere formulation for sustained release; no titration needed |
Evidence Grade
GRADE A
Safety & Contraindications
- FDA-approved since 2005 (Byetta) and 2012 (Bydureon) with extensive long-term safety data
- Black box warning: thyroid C-cell tumors in rodents; contraindicated with MTC/MEN2 history
- Common GI side effects: nausea (44% Byetta, 20% Bydureon), vomiting, diarrhea - typically diminish over time
- Injection site reactions with Bydureon (nodules from microsphere depot) in ~10% of patients
- Risk of pancreatitis: monitor for signs and symptoms, discontinue if suspected
- Contraindicated in severe renal impairment (eGFR <30 mL/min) or end-stage renal disease